BLAINTRAMUSCULARINJECTABLE
Approved
Jun 2021
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
2/8 — Basic
RYLAZE (asparaginase erwinia chrysanthemi (recombinant)-rywn) by Jazz Pharmaceuticals. Approved for asparagine-specific enzyme [epc]. First approved in 2021.
Drug data last refreshed 7h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RYLAZE is a recombinant asparaginase enzyme derived from Erwinia chrysanthemi, approved as an asparagine-specific biologic injectable. It depletes asparagine in blood and cerebrospinal fluid, inhibiting protein synthesis in asparagine-dependent malignancies. The drug is used as a component of multi-agent chemotherapy regimens for hematologic cancers.
Peak
RYLAZE is in peak commercial stage with moderate competitive pressure (30%), indicating active field promotion and stable commercial team investment.
Mechanism of Action
Pharmacologic Class:
Asparagine-specific Enzyme
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on RYLAZE offers exposure to specialty oncology commercialization in a peak-stage injectable biologic. Roles focus on payer management, hematology/oncology physician engagement, and hospital formulary penetration rather than pipeline advancement.
Brand ManagerMedical Science Liaison (MSL)
Worked on RYLAZE at Jazz Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.